{
    "nct_id": "NCT03697564",
    "official_title": "Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial)",
    "inclusion_criteria": "* Histologically or cytologically confirmed pancreatic adenocarcinoma with metastasis\n* Must be off their prior cytotoxic regimen a minimum of two weeks but no more than four weeks from initiating trial treatment.\n\nMeasurable disease by RECIST 1.1.\n\nDemonstrate adequate organ function\n\nNormal Vitamin D level.\n\nAble to submit an archival tumor specimen (primary or metastatic site). Patients with cytology only that do not have adequate archived tumor specimen available, will require a baseline biopsy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is currently participating and receiving trial therapy or has participated in a trial of an investigational agent and received trial therapy or used an investigational device within 3 weeks of the first dose of trial treatment.\n* Hypersensitivity to cabiralizumab, nivolumab, or gemcitabine or any of its excipients.\n* Previous malignancies (except non-melanoma skin cancers, and in situ bladder, gastric, colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period.\n* Evidence of central nervous system (CNS) metastasis\n* Participants with active, known, or suspected autoimmune disease.\n* Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels.\n* Uncontrolled or significant cardiovascular disease\n* Prior organ allograft or allogeneic bone marrow transplantation.\n* Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative colitis.\n* Evidence of coagulopathy or bleeding diathesis.\n* Has received prior therapy with a CSF-1R pathway inhibitors, anti-PD-1, anti-PD-L1, anti PD-L2, anti-CTLA-4.",
    "miscellaneous_criteria": ""
}